Portfolio

LUNAC Therapeutics Completes Additional Financing Round

Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies. Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants, announces it has raised £4.75 million in an…

DUNAD Therapeutics Emerges to Develop Next-Generation Small Molecule Therapeutics Based on First Tuneable Targeted Protein Degradation Technology

New UK company backed by Epidarex Capital emerges from stealth Cambridge, UK, March 23, 2021 – Dunad Therapeutics (“Dunad”) emerges today to develop next-generation small molecule therapeutics based on its highly differentiated, tuneable and targeted protein degradation technology. Dunad, secured initial financing from Epidarex Capital,…

Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements in key clinical outcomes Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the…

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) —  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two…

LUNAC Therapeutics Wins Start Up of the Year at Bionow Awards

Leeds, UK, 5 February 2021:  LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants, has been named as this year’s Start Up of the Year winner at the 19th Bionow Awards.  The 19th Bionow Awards took place…